Last $68.28 USD
Change Today -0.45 / -0.65%
Volume 1.1M
AZN On Other Exchanges
Symbol
Exchange
New York
Xetra
OTC US
Mexico
Berlin
As of 8:04 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

Audit Committee* - astrazeneca plc-spons adr (AZN)

Name (Connections)Board RelationshipsTitleKey Developments
Jean-Philippe Courtois 72 RelationshipsNon-Executive Director and Member of Audit CommitteeAstrazeneca Announces Revised Results for the Year 2003 and First Half of 2004
10/25/04
Donald Burlington M.D. 32 RelationshipsNon-Executive Director, Member of Science Committee and Member of Audit CommitteeAstraZeneca's Marketing Of Drugs Is Investigated
03/11/03
Shriti Vadera MA 42 RelationshipsNon-Executive Director and Member of Audit Committee 
Ann Cairns MSc 13 RelationshipsNon-Executive Director and Member of Audit Committee 

Compensation Committee* - astrazeneca plc-spons adr (AZN)

Name (Connections)Board RelationshipsTitle
Graham Chipchase 20 RelationshipsNon-Executive Director and Member of Remuneration Committee
Dame Rothwell B.Sc, Ph.D., DSc, FMedSci, FRS 13 RelationshipsNon-Executive Director, Chairman of Science Committee, Member of Nomination & Governance Committee and Member of Remuneration Committee
John Varley BA, MA (Oxon) 46 RelationshipsSenior Independent Non-Executive Director, Chairman of Remuneration Committee and Member of Nomination & Governance Committee
AZN Compensation vs. Industry
1.1M
384.5K
Chief Executive Officer
113.0K
257.8K
Chief Financial Officer
Share price activity for ASTRAZENECA PLC-SPONS ADR (AZN)
52 Week Price Performance
AZN
Industry Average

Nominating Committee* - astrazeneca plc-spons adr (AZN)

Name (Connections)Board RelationshipsTitleKey Developments
Dame Rothwell B.Sc, Ph.D., DSc, FMedSci, FRS 13 RelationshipsNon-Executive Director, Chairman of Science Committee, Member of Nomination & Governance Committee and Member of Remuneration CommitteeAstraZeneca PLC Proposes Board Changes
02/17/15
John Varley BA, MA (Oxon) 46 RelationshipsSenior Independent Non-Executive Director, Chairman of Remuneration Committee and Member of Nomination & Governance CommitteeBioInvent International AB Appoints Anna Wickenberg as Vice President Clinical Development
01/22/15

Corporate Governance Committee* - astrazeneca plc-spons adr (AZN)

Name (Connections)Board RelationshipsTitle
Dame Rothwell B.Sc, Ph.D., DSc, FMedSci, FRS 13 RelationshipsNon-Executive Director and Member of Remuneration Committee
John Varley BA, MA (Oxon) 46 RelationshipsNon-Executive Director, Chairman of Science Committee, Member of Nomination & Governance Committee and Member of Remuneration Committee
AZN and Competitor
Insiders vs. External
Board
14%
86%
AstraZeneca PLC
9%
91%
Biogen Idec Inc.
13%
87%
Celgene Corporation
13%
87%
Eli Lilly and Company
13%
87%
Novo Nordisk A/S
11%
89%
AbbVie Inc.
Insiders
External Board Members
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AZN:US $68.28 USD -0.45

AZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $59.62 USD -0.84
Biogen Idec Inc $412.79 USD -3.00
Celgene Corp $118.47 USD -1.84
Eli Lilly & Co $70.37 USD -0.75
Novo Nordisk A/S kr315.00 DKK -2.50
View Industry Companies
 

Industry Analysis

AZN

Industry Average

Valuation AZN Industry Range
Price/Earnings 69.8x
Price/Sales 3.3x
Price/Book 4.4x
Price/Cash Flow 69.8x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC-SPONS ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.